International Journal of Clinical Case Reports 2024, Vol.14, No.4, 202-209 http://medscipublisher.com/index.php/ijccr 206 (AR-V7), a key driver of castration-resistant prostate cancer (CRPC). Studies indicate that silencing HOXB13 in CRPC models reduces AR-V7 oncogenic functions, providing a potential therapeutic target for AR-V7-driven tumors (Chen et al., 2018). Another promising strategy involves inhibiting acetylated HOXB13, which primes CRPC for AR antagonism by regulating super-enhancer genes that drive cancer progression (Nguyen et al., 2022). These findings suggest that targeting HOXB13 could be an effective approach in personalized treatment for prostate cancer. 5.2 Potential impact of HOXB13 gene variants on immunotherapy response The impact of HOXB13 gene variants on immunotherapy responses is an emerging area of research. Although the interaction between HOXB13 and immune checkpoint inhibitors has not been fully explored, its role in regulating androgen receptor-driven pathways and tumor progression may influence immune evasion mechanisms in prostate cancer. Current research focuses on how targeting HOXB13-regulated pathways might improve the efficacy of immune checkpoint blockade therapies. Further studies are needed to clarify the direct link between HOXB13 expression and immunotherapy outcomes in metastatic CRPC (Nguyen et al., 2022). 5.3 Relationship betweenHOXB13 gene mutations and resistance to chemotherapy or hormonal therapy HOXB13 mutations, particularly G84E, are associated with resistance to traditional treatments, such as androgen deprivation therapy (ADT) and chemotherapy. Research has shown that HOXB13 co-regulates AR splice variants, including AR-V7, which are known to drive resistance to AR-targeting agents like enzalutamide and abiraterone (Liu et al., 2021). By promoting AR-V7 expression, HOXB13 enables tumor cells to evade hormonal therapies, making it a key factor in therapy resistance (Chen et al., 2018). Targeting HOXB13 in conjunction with AR antagonists may improve treatment responses, particularly in advanced cases of castration-resistant prostate cancer (Sipeky et al., 2018). 6 Future Research Directions and Challenges 6.1 Other potential mechanisms and functions of HOXB13 gene variants While the role of HOXB13 mutations, particularly G84E, in prostate cancer is well-documented, ongoing research is needed to uncover additional mechanisms and functions of HOXB13 in prostate cancer progression. Recent studies suggest that HOXB13 influences key oncogenic pathways by interacting with chromatin remodelers and transcription factors like androgen receptors (AR) (Nerlakanti et al., 2018; Lu et al., 2021). Beyond AR, HOXB13 also impacts genes involved in mitotic regulation and cancer cell migration, pointing to its broader role in cancer metastasis. The identification of downstream targets, such as the mitotic kinase CIT and the tumor suppressor HSPB8, has highlighted novel pathways that HOXB13 might regulate in metastatic prostate cancer, offering opportunities for future therapeutic interventions (Yao et al., 2019). 6.2 Necessity for large-scale population studies onHOXB13 gene variants The current data on HOXB13 gene variants, such as G84E, have predominantly focused on European populations. However, to understand the true global impact of these variants, large-scale population studies across diverse ethnic groups are essential. Such studies can reveal ethnic differences in the prevalence of HOXB13 mutations and assess their association with prostate cancer risk in non-European populations (Schnoeller et al., 2015). For example, the G132E and F127C variants have been associated with prostate cancer risk in Japanese men, illustrating the importance of expanding research to other populations (Kurihara et al., 2022). Additionally, combining genetic data from large cohorts like the UK Biobank has proven effective in identifying novel risk loci beyond HOXB13, which further emphasizes the need for large-scale, multi-ethnic studies (Emami et al., 2020). 6.3 How to apply HOXB13 gene variant research in clinical practice The integration of HOXB13 variant research into clinical practice holds great promise for improving prostate cancer diagnosis, prognosis, and treatment. However, the challenge lies in translating genetic findings into practical tools for clinicians (Kim et al., 2020). HOXB13 variants such as G84E should be incorporated into genetic screening panels for early detection and risk assessment, particularly in
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==